Array Biopharma Inc (ARRY) 3.50 $ARRY Array (AR
Post# of 273257
Posted On: 09/03/2016 9:16:42 AM
Array Biopharma Inc (ARRY) 3.50 $ARRY
Array (ARRY) Oncology Drug Accepted for Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:29AM CDT
Array BioPharma (ARRY) announced that the FDA has accepted a New Drug Application (NDA) for its oncology candidate, binimetinib.
CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33), ARRY: 3.50 (-0.02), NVS: 79.38 (+1.11)
Array BioPharma Announces FDA Acceptance of Binimetinib NDA for Patients with Advanced NRAS-Mutant Melanoma
PR Newswire - Thu Sep 01, 7:00AM CDT
Array BioPharma (Nasdaq: ARRY) today announced that the FDA has accepted its New Drug Application (NDA) for binimetinib with a target action date under the Prescription Drug User Fee Act (PDUFA) of June 30, 2017. Array completed its NDA submission of binimetinib in late June 2016 based on findings from the pivotal Phase 3 NEMO (NRAS MELANOMA AND MEK INHIBITOR) trial in patients with NRAS-mutant melanoma. The FDA also indicated that it plans to hold an advisory committee meeting (ODAC) as part of the review process. As previously reported, Array is currently preparing for an Application Orientation Meeting (AOM) with the FDA in September 2016, which it expects will include a discussion of the NDA package including clinical risk / benefit.
ARRY: 3.50 (-0.02)
Array (ARRY) Presents Positive Cardiovascular Trial Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 10:28AM CDT
Array BioPharma (ARRY) presented positive results from a phase II study on its pipeline candidate, ARRY-797, at the European Society of Cardiology Congress 2016 in Rome, Italy.
ANIP: 59.86 (-1.56), AZN: 33.31 (+0.71), ARRY: 3.50 (-0.02)
Array BioPharma To Present At The Wells Fargo Securities Healthcare Conference
PR Newswire - Wed Aug 31, 8:00AM CDT
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Wells Fargo Securities Healthcare Conference in Boston. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
WFC: 50.55 (+0.12), ARRY: 3.50 (-0.02)
Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress
PR Newswire - Tue Aug 30, 7:00AM CDT
Array BioPharma (Nasdaq: ARRY) announced today results from a Phase 2 study of ARRY-797, an oral, selective p38 mitogen-activated protein kinase inhibitor, in patients with lamin A/C-related dilated cardiomyopathy (LMNA-related DCM), a rare, degenerative cardiovascular disease caused by mutations in the LMNA gene and characterized by poor prognosis. The trial results were presented at the European Society of Cardiology Congress 2016 in Rome, Italy. The results demonstrated an absolute mean change from baseline of 69 meters on the six-minute walk test (6MWT) at week 12, the study's primary endpoint (baseline 6MWT ranged from 246 to 412 meters). This magnitude of improvement exceeded historical benchmarks for 6MWT that have served as the basis for recent approvals of other drugs in other rare diseases. ARRY-797 administration also resulted in sustained improvements in N-terminal pro-brain natriuretic peptide (NT-proBNP), functional capacity and cardiac function through 48 weeks in LMNA-related DCM patients. Patients who rolled over to a continuing treatment protocol maintained improvements in the 6MWT and NT-proBNP levels through 72 weeks of treatment. Other secondary endpoints measured including echocardiographic measures of left and right ventricular function and patient-reported outcomes using the Kansas City Cardiomyopathy Questionnaire (KCCQ), both mirrored the favorable improvements seen with the 6MWT.
ARRY: 3.50 (-0.02)
Array BioPharma Announces Clinical Data Presentation On ARRY-797 At The 2016 European Society Of Cardiology Congress
PR Newswire - Fri Aug 19, 2:26PM CDT
Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from a Phase 2 study of ARRY-797 will be presented at the 2016 European Society of Cardiology (ESC) Congress, which will be held August 27 - 31, 2016 in Rome, Italy.
ARRY: 3.50 (-0.02)
Shareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating Array BioPharma Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Wed Aug 10, 9:55AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Array BioPharma Inc. (NASDAQ: ARRY).
ARRY: 3.50 (-0.02)
After Yesterday's Decline of 22.70%, Array Biopharma Offers Investors Better Value
Comtex SmarTrend(R) - Tue Aug 09, 4:32PM CDT
Array Biopharma (NASDAQ:ARRY) traded in a range yesterday that spanned from a low of $3.40 to a high of $3.95. Yesterday, the shares fell 22.7%, which took the trading range below the 3-day low of $4.01 on volume of 5.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARRY: 3.50 (-0.02)
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
PR Newswire - Tue Aug 09, 1:01AM CDT
AstraZeneca (LON/STO/NYSE: AZN) today announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-line treatment in patients with KRAS mutation-positive (KRASm) locally-advanced or metastatic non-small cell lung cancer (NSCLC). Array BioPharma (NASDAQ: ARRY) was informed of these results on Monday, August 8, 2016.
AZN: 33.31 (+0.71), ARRY: 3.50 (-0.02)
Array BioPharma (ARRY) in Focus: Stock Moves 9.3% Higher
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 7:25AM CDT
Array BioPharma Inc. (ARRY) moved big last session, as its shares jumped over 9% on the day.
ANIK: 47.89 (-0.05), ARRY: 3.50 (-0.02)
Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2016
PR Newswire - Thu Aug 04, 7:00AM CDT
Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule cancer therapies, today reported results for its fiscal fourth quarter and full year ended June 30, 2016 and provided an update on the progress of its key clinical development programs.
ARRY: 3.50 (-0.02)
Array BioPharma Announces Appointment Of Jason Haddock As Chief Financial Officer
PR Newswire - Thu Jul 28, 7:00AM CDT
Array BioPharma (NASDAQ: ARRY) ("Array"
, a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, announced it has appointed Jason Haddock as Chief Financial Officer (CFO). Mr. Haddock's appointment was effective today and he will be replacing David Horin, who had been acting as Array's interim CFO. We wish to thank Mr. Horin for his service and commitment to Array. He will continue to provide services to Array on a consulting basis.
ARRY: 3.50 (-0.02)
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2016 On August 4, 2016
PR Newswire - Wed Jul 27, 3:56PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2016 and hold a conference call to discuss those results on Thursday, August 4, 2016. Ron Squarer, Chief Executive Officer, will lead the call.
ARRY: 3.50 (-0.02)
Array Presents Full Results from Phase 3 NEMO Study
PR Newswire - Mon Jun 06, 1:15PM CDT
Array BioPharma (Nasdaq: ARRY) announced full results at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract No. 9500) from the pivotal Phase 3 NEMO (NRAS MELANOMA AND MEK INHBITOR) trial of binimetinib. The study found binimetinib significantly extended median progression-free survival (PFS), the study's primary endpoint, at 2.8 months, as compared with 1.5 months observed with dacarbazine [hazard ratio (HR)=0.62 (95% CI 0.47-0.80), p<0.001] - the first trial to ever meet a PFS endpoint in patients with advanced NRAS-mutant melanoma. In the pre-specified subset of patients who received prior treatment with immunotherapy, including ipilimumab, nivolumab or pembrolizumab, patients who received binimetinib experienced 5.5 months of median PFS (95% CI, 2.8-7.6), compared with 1.6 months for those receiving treatment with dacarbazine (95% CI, 1.5-2.
.
ARRY: 3.50 (-0.02)
Encorafenib-based Regimens Provide Improved PFS and OS in Difficult-to-Treat BRAF-Mutant Colorectal Cancer Compared to Historical Benchmarks
PR Newswire - Sat Jun 04, 8:00AM CDT
Array BioPharma (Nasdaq: ARRY) announced today updated results from a Phase 2 study of the combination of encorafenib and cetuximab, with or without alpelisib, in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). BRAFm CRC represents a difficult-to-treat subtype of colorectal cancer that impacts 8 to 15 percent of patients. Data from this study suggest that median overall survival (OS) for these patients may exceed one year which is more than double historical published benchmarks for this population. These data were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract No. 3544).
ARRY: 3.50 (-0.02)
Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt, Germany Announce Phase 3 BEACON CRC Trial
PR Newswire - Sat Jun 04, 8:00AM CDT
Array BioPharma (Nasdaq: ARRY), Pierre Fabre and Merck KGaA, Darmstadt, Germany, today jointly initiated the BEACON CRC (Binimetinib, Encorafenib And Cetuximab Combined to treat BRAF-mutant Colorectal Cancer) trial, a randomized, global Phase 3 clinical trial designed to assess the safety and efficacy of binimetinib (MEK inhibitor), encorafenib (BRAF inhibitor) and Erbitux (monoclonal antibody) in comparison to Erbitux and irinotecan-based therapy in patients with BRAF-mutant colorectal cancer (BRAFm CRC). The primary endpoint is overall survival (OS) and key secondary endpoints include progression-free survival (PFS) and objective response rate (ORR).
ARRY: 3.50 (-0.02)
Array BioPharma To Present At The Jefferies 2016 Global Healthcare Conference
PR Newswire - Thu Jun 02, 1:20PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Jefferies 2016 Global Healthcare Conference in New York City. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
ARRY: 3.50 (-0.02)
Array BioPharma Announces Key Data from NRAS-mutant Melanoma and BRAF-mutant Colorectal Cancer ASCO 2016 Presentations
PR Newswire - Wed May 18, 4:05PM CDT
Array BioPharma (NASDAQ: ARRY) will present additional data on its late-stage candidates binimetinib and encorafenib in NRAS-mutant melanoma and BRAF-mutant colorectal cancer, respectively, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on June 3-7.
ARRY: 3.50 (-0.02)
Array BioPharma To Present At The Bank of America Merrill Lynch HealthCare Conference
PR Newswire - Thu May 05, 6:00PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas. The public is welcome to participate in the conferences through a webcast on the Array BioPharma website.
ARRY: 3.50 (-0.02)
Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2016
PR Newswire - Tue May 03, 7:00AM CDT
Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule cancer therapies, today reported results for its fiscal year third quarter ending March 31, 2016 and provided an update on the progress of its key clinical development programs.
ARRY: 3.50 (-0.02)
Array (ARRY) Oncology Drug Accepted for Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:29AM CDT
Array BioPharma (ARRY) announced that the FDA has accepted a New Drug Application (NDA) for its oncology candidate, binimetinib.
CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33), ARRY: 3.50 (-0.02), NVS: 79.38 (+1.11)
Array BioPharma Announces FDA Acceptance of Binimetinib NDA for Patients with Advanced NRAS-Mutant Melanoma
PR Newswire - Thu Sep 01, 7:00AM CDT
Array BioPharma (Nasdaq: ARRY) today announced that the FDA has accepted its New Drug Application (NDA) for binimetinib with a target action date under the Prescription Drug User Fee Act (PDUFA) of June 30, 2017. Array completed its NDA submission of binimetinib in late June 2016 based on findings from the pivotal Phase 3 NEMO (NRAS MELANOMA AND MEK INHIBITOR) trial in patients with NRAS-mutant melanoma. The FDA also indicated that it plans to hold an advisory committee meeting (ODAC) as part of the review process. As previously reported, Array is currently preparing for an Application Orientation Meeting (AOM) with the FDA in September 2016, which it expects will include a discussion of the NDA package including clinical risk / benefit.
ARRY: 3.50 (-0.02)
Array (ARRY) Presents Positive Cardiovascular Trial Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 10:28AM CDT
Array BioPharma (ARRY) presented positive results from a phase II study on its pipeline candidate, ARRY-797, at the European Society of Cardiology Congress 2016 in Rome, Italy.
ANIP: 59.86 (-1.56), AZN: 33.31 (+0.71), ARRY: 3.50 (-0.02)
Array BioPharma To Present At The Wells Fargo Securities Healthcare Conference
PR Newswire - Wed Aug 31, 8:00AM CDT
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Wells Fargo Securities Healthcare Conference in Boston. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
WFC: 50.55 (+0.12), ARRY: 3.50 (-0.02)
Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress
PR Newswire - Tue Aug 30, 7:00AM CDT
Array BioPharma (Nasdaq: ARRY) announced today results from a Phase 2 study of ARRY-797, an oral, selective p38 mitogen-activated protein kinase inhibitor, in patients with lamin A/C-related dilated cardiomyopathy (LMNA-related DCM), a rare, degenerative cardiovascular disease caused by mutations in the LMNA gene and characterized by poor prognosis. The trial results were presented at the European Society of Cardiology Congress 2016 in Rome, Italy. The results demonstrated an absolute mean change from baseline of 69 meters on the six-minute walk test (6MWT) at week 12, the study's primary endpoint (baseline 6MWT ranged from 246 to 412 meters). This magnitude of improvement exceeded historical benchmarks for 6MWT that have served as the basis for recent approvals of other drugs in other rare diseases. ARRY-797 administration also resulted in sustained improvements in N-terminal pro-brain natriuretic peptide (NT-proBNP), functional capacity and cardiac function through 48 weeks in LMNA-related DCM patients. Patients who rolled over to a continuing treatment protocol maintained improvements in the 6MWT and NT-proBNP levels through 72 weeks of treatment. Other secondary endpoints measured including echocardiographic measures of left and right ventricular function and patient-reported outcomes using the Kansas City Cardiomyopathy Questionnaire (KCCQ), both mirrored the favorable improvements seen with the 6MWT.
ARRY: 3.50 (-0.02)
Array BioPharma Announces Clinical Data Presentation On ARRY-797 At The 2016 European Society Of Cardiology Congress
PR Newswire - Fri Aug 19, 2:26PM CDT
Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from a Phase 2 study of ARRY-797 will be presented at the 2016 European Society of Cardiology (ESC) Congress, which will be held August 27 - 31, 2016 in Rome, Italy.
ARRY: 3.50 (-0.02)
Shareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating Array BioPharma Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Wed Aug 10, 9:55AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Array BioPharma Inc. (NASDAQ: ARRY).
ARRY: 3.50 (-0.02)
After Yesterday's Decline of 22.70%, Array Biopharma Offers Investors Better Value
Comtex SmarTrend(R) - Tue Aug 09, 4:32PM CDT
Array Biopharma (NASDAQ:ARRY) traded in a range yesterday that spanned from a low of $3.40 to a high of $3.95. Yesterday, the shares fell 22.7%, which took the trading range below the 3-day low of $4.01 on volume of 5.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARRY: 3.50 (-0.02)
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
PR Newswire - Tue Aug 09, 1:01AM CDT
AstraZeneca (LON/STO/NYSE: AZN) today announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-line treatment in patients with KRAS mutation-positive (KRASm) locally-advanced or metastatic non-small cell lung cancer (NSCLC). Array BioPharma (NASDAQ: ARRY) was informed of these results on Monday, August 8, 2016.
AZN: 33.31 (+0.71), ARRY: 3.50 (-0.02)
Array BioPharma (ARRY) in Focus: Stock Moves 9.3% Higher
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 7:25AM CDT
Array BioPharma Inc. (ARRY) moved big last session, as its shares jumped over 9% on the day.
ANIK: 47.89 (-0.05), ARRY: 3.50 (-0.02)
Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2016
PR Newswire - Thu Aug 04, 7:00AM CDT
Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule cancer therapies, today reported results for its fiscal fourth quarter and full year ended June 30, 2016 and provided an update on the progress of its key clinical development programs.
ARRY: 3.50 (-0.02)
Array BioPharma Announces Appointment Of Jason Haddock As Chief Financial Officer
PR Newswire - Thu Jul 28, 7:00AM CDT
Array BioPharma (NASDAQ: ARRY) ("Array"
, a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, announced it has appointed Jason Haddock as Chief Financial Officer (CFO). Mr. Haddock's appointment was effective today and he will be replacing David Horin, who had been acting as Array's interim CFO. We wish to thank Mr. Horin for his service and commitment to Array. He will continue to provide services to Array on a consulting basis. ARRY: 3.50 (-0.02)
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2016 On August 4, 2016
PR Newswire - Wed Jul 27, 3:56PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2016 and hold a conference call to discuss those results on Thursday, August 4, 2016. Ron Squarer, Chief Executive Officer, will lead the call.
ARRY: 3.50 (-0.02)
Array Presents Full Results from Phase 3 NEMO Study
PR Newswire - Mon Jun 06, 1:15PM CDT
Array BioPharma (Nasdaq: ARRY) announced full results at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract No. 9500) from the pivotal Phase 3 NEMO (NRAS MELANOMA AND MEK INHBITOR) trial of binimetinib. The study found binimetinib significantly extended median progression-free survival (PFS), the study's primary endpoint, at 2.8 months, as compared with 1.5 months observed with dacarbazine [hazard ratio (HR)=0.62 (95% CI 0.47-0.80), p<0.001] - the first trial to ever meet a PFS endpoint in patients with advanced NRAS-mutant melanoma. In the pre-specified subset of patients who received prior treatment with immunotherapy, including ipilimumab, nivolumab or pembrolizumab, patients who received binimetinib experienced 5.5 months of median PFS (95% CI, 2.8-7.6), compared with 1.6 months for those receiving treatment with dacarbazine (95% CI, 1.5-2.
. ARRY: 3.50 (-0.02)
Encorafenib-based Regimens Provide Improved PFS and OS in Difficult-to-Treat BRAF-Mutant Colorectal Cancer Compared to Historical Benchmarks
PR Newswire - Sat Jun 04, 8:00AM CDT
Array BioPharma (Nasdaq: ARRY) announced today updated results from a Phase 2 study of the combination of encorafenib and cetuximab, with or without alpelisib, in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). BRAFm CRC represents a difficult-to-treat subtype of colorectal cancer that impacts 8 to 15 percent of patients. Data from this study suggest that median overall survival (OS) for these patients may exceed one year which is more than double historical published benchmarks for this population. These data were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract No. 3544).
ARRY: 3.50 (-0.02)
Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt, Germany Announce Phase 3 BEACON CRC Trial
PR Newswire - Sat Jun 04, 8:00AM CDT
Array BioPharma (Nasdaq: ARRY), Pierre Fabre and Merck KGaA, Darmstadt, Germany, today jointly initiated the BEACON CRC (Binimetinib, Encorafenib And Cetuximab Combined to treat BRAF-mutant Colorectal Cancer) trial, a randomized, global Phase 3 clinical trial designed to assess the safety and efficacy of binimetinib (MEK inhibitor), encorafenib (BRAF inhibitor) and Erbitux (monoclonal antibody) in comparison to Erbitux and irinotecan-based therapy in patients with BRAF-mutant colorectal cancer (BRAFm CRC). The primary endpoint is overall survival (OS) and key secondary endpoints include progression-free survival (PFS) and objective response rate (ORR).
ARRY: 3.50 (-0.02)
Array BioPharma To Present At The Jefferies 2016 Global Healthcare Conference
PR Newswire - Thu Jun 02, 1:20PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Jefferies 2016 Global Healthcare Conference in New York City. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
ARRY: 3.50 (-0.02)
Array BioPharma Announces Key Data from NRAS-mutant Melanoma and BRAF-mutant Colorectal Cancer ASCO 2016 Presentations
PR Newswire - Wed May 18, 4:05PM CDT
Array BioPharma (NASDAQ: ARRY) will present additional data on its late-stage candidates binimetinib and encorafenib in NRAS-mutant melanoma and BRAF-mutant colorectal cancer, respectively, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on June 3-7.
ARRY: 3.50 (-0.02)
Array BioPharma To Present At The Bank of America Merrill Lynch HealthCare Conference
PR Newswire - Thu May 05, 6:00PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas. The public is welcome to participate in the conferences through a webcast on the Array BioPharma website.
ARRY: 3.50 (-0.02)
Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2016
PR Newswire - Tue May 03, 7:00AM CDT
Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule cancer therapies, today reported results for its fiscal year third quarter ending March 31, 2016 and provided an update on the progress of its key clinical development programs.
ARRY: 3.50 (-0.02)
(0)
(0)Scroll down for more posts ▼